In NSCLC, elevated levels of MUC3A correlate with increased tumor growth, reduced sensitivity to therapies such as radiation, and the upregulation of immune checkpoint proteins like PD-L1, which facilitate immune evasion by tumors (30, 31). This evidence concerns the gene MUC3A and non-small cell lung carcinoma.